ACTRN12618001640291
Recruiting
未知
Additive diagnostic value of prostate specific membrane antigen (PSMA) positron emission tomography (PET) to multiparametric magnetic resonance imaging (mpMRI) in the diagnostic setting: Ability to reduce unnecessary prostate biopsies in men being investigated for prostate cancer.
St Vincent's Hospital0 sites200 target enrollmentOctober 4, 2018
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- St Vincent's Hospital
- Enrollment
- 200
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male, aged 18 years or over
- •Suspicion or prostate cancer with either an abnormal DRE OR PSA greater than age specific reference range on two or more occasions
- •No previously diagnosed prostate cancer
- •No previous prostate biopsies
- •Has undergone an mpMRI within the last 6 months, or scheduled to undergo an mpMRI prior to biopsy
- •Ability to give written informed consent, participate in and comply with the study
Exclusion Criteria
- •Previous diagnosis of PCa
- •Previous prostate biopsies
- •Inability/ incapacity to provide own consent
- •PSA \>20ng/ml
- •greater than or equal to cT3 on DRE
- •Contraindication to MRI, including but not restricted to:
- •oPacemaker or other electronic implant
- •oAllergy or contraindiation to MRI contrast, e.g. renal failure (eGFR \<30mL/min)
- •oShrapnel, tattoos, non\-removable body piercings (relative contraindication)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
Diagnostic Performance of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Pre-operative Lymph Node Assessment in Intermediate and High-risk Nonmetastasic Prostate Cancer2024-516319-25-00Centre Hospitalier Regional Et Universitaire De Brest159
Terminated
Not Applicable
The use of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) scans and Magnetic Resonance Imaging (MRI) to better guide high dose radiotherapy for men with high-risk prostate cancer as a means to improve clinical and quality of life outcomes.High risk prostate cancerACTRN12617000816358The Garvan Institute of Medical Research20
Recruiting
Not Applicable
Detection of clinically significant prostate cancer with MRI-TRUS fusion image-guided biopsy: comparison of the evaluation system (PI-RADS category vs. PI-RADS + US evalutaion)Suspected prostate cancerJPRN-UMIN000050631Tokai University80
Recruiting
Not Applicable
The added value of MRI for detection of prostate cancer: validation with MR guided biopsies, fusion of MRI and transrectal ultrasound guided biopsies and TRUS guided biopsies.prostate cancerprostate carcinoma10038594NL-OMON32545niversitair Medisch Centrum Sint Radboud60
Unknown
Not Applicable
The Value of PSMA-PET Compared With Multi-parametric MRI in the Detection Prostate LesionsProstate CancerNCT03174054Assuta Medical Center70